NasdaqCM - Nasdaq Real Time Price USD

Tivic Health Systems, Inc. (TIVC)

Compare

0.2648

-0.0130

(-4.68%)

At close: January 14 at 4:00:00 PM EST

0.2649

+0.00

+(0.04%)

After hours: January 14 at 5:49:11 PM EST

CEO Letter to Shareholders Issued by Tivic Health

FREMONT, Calif., December 23, 2024--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, today released its annual CEO letter to shareholders.

Business Wire 22 days ago

TIVC
-4.68%
Tivic Health Systems Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$1.48 loss in 3Q 2023)

Tivic Health Systems ( NASDAQ:TIVC ) Third Quarter 2024 Results Key Financial Results Revenue: US$126.0k (down 55% from...

Simply Wall St. last month

TIVC
-4.68%
Tivic hits enrolment target for vagus nerve stimulation trial

Tivic has not yet identified clinical targets as the company optimises its non-invasive technology.

Medical Device Network last month

TIVC
-4.68%
Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update

FREMONT, Calif., November 15, 2024--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced third quarter and nine-months ended September, 30, 2024 financial results and discussed growth strategies based on its novel, patent-pending vagus nerve stimulation (VNS) science and device technology.

Business Wire last month

TIVC
-4.68%
Enrollment Complete in Tivic Health Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device

FREMONT, Calif., November 14, 2024--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that full enrollment has been completed in the optimization study for Tivic Health’s patent pending, non-invasive vagus nerve stimulation (VNS) device.

Business Wire last month

TIVC
-4.68%
Tivic Health Validates European Patents in Great Britain, Germany, and France

FREMONT, Calif., November 12, 2024--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicinal devices, announced today that it has validated two granted European Patent Office (EPO) patents in Great Britain, Germany, and France. The Company believes these validations are an important step toward securing the foundation for an international market position.

Business Wire 2 months ago

TIVC
-4.68%
Tivic Health Systems, Inc. to Report Third Quarter 2024 Financial Results on November 14

FREMONT, Calif., November 07, 2024--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it will report financial results on Thursday, November 14 after market close. The release will be followed by a pre-recorded conference call and webcast at 1:30 p.m. PST / 4:30 p.m. EST. Shareholders, interested parties, and prospective investors are invited to join via dial in or webcast. The company invites questions to b

Business Wire 2 months ago

TIVC
-4.68%
First Subject Enrolled in Tivic Health’s Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device

FREMONT, Calif., October 29, 2024--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that the first study subject has been enrolled in the optimization study for Tivic Health’s patent pending, non-invasive vagus nerve stimulation device.

Business Wire 2 months ago

TIVC
-4.68%
Tivic Health CEO Jennifer Ernst to Present at New York BioFuture 2024

SAN FRANCISCO, October 24, 2024--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that CEO Jennifer Ernst will presenting at the upcoming BioFuture 2024 Conference in New York, October 28-30. Ms. Ernst’s presentation, Tuesday, October 29 at 2:30 p.m. EDT, will focus on the company’s advances in bioelectronic medicine, including its recently released data on a new approach to vagus nerve stimulation.

Business Wire 2 months ago

TIVC
-4.68%
Tivic Health Gets Institutional Review Board's Approval for ncVNS Optimization Study

Tivic Health Gets Institutional Review Board's Approval for ncVNS Optimization Study

PREMIUM
MT Newswires 3 months ago

TIVC
-4.68%
Tivic Health Receives Approval from Institutional Review Board for ncVNS Optimization Study, Readies for Enrollment

SAN FRANCISCO, September 18, 2024--Tivic Health® Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it has received approval from The Feinstein Institutes’ Institutional Review Board for the next phase of clinical work on its non-invasive cervical vagus nerve stimulation ("ncVNS") approach.

Business Wire 3 months ago

TIVC
-4.68%
Tivic Health Accelerates VNS Commercial Strategy Development

SAN FRANCISCO, September 17, 2024--Tivic Health® Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it has partnered with Fletcher Spaght ("FSI"), a leading healthcare growth strategy firm, to accelerate development of its commercial strategy for non-invasive cervical vagus nerve stimulation ("ncVNS").

Business Wire 3 months ago

TIVC
-4.68%
Tivic Health Appoints Lisa Wolf as Interim Chief Financial Officer

SAN FRANCISCO, September 13, 2024--Tivic Health® Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce the appointment of Lisa Wolf as Interim Chief Financial Officer (CFO) of the company, effective October 1, 2024. Ms. Wolf will take over from Kimberly Bambach, who has served as the company’s interim CFO since April 2023. Ms. Bambach will continue with Tivic in an advisory role for strategic transactio

Business Wire 3 months ago

TIVC
-4.68%
Tivic Reports Second Quarter 2024 Financial Results

SAN FRANCISCO, August 14, 2024--Tivic Health® Systems, Inc. ("Tivic", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its second quarter 2024 financial results and discussed growth strategies based on its investments in vagus nerve stimulation ("VNS").

Business Wire 4 months ago

TIVC
-4.68%
Tivic Health to Report Q2 2024 Financial Results and Corporate Update on August 14th Via Conference Call and Webcast

SAN FRANCISCO, August 06, 2024--Tivic Health® Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q2 2024 financial results and a corporate update via pre-recorded conference call and webcast on Wednesday, August 14 at 1:30 PM PT / 4:30 PM ET. Current shareholders, interested individuals and future investors are encouraged to join the webcast to hear the company executives provide a c

Business Wire 5 months ago

TIVC
-4.68%
Tivic Announces 2024 Annual Meeting of Stockholders

SAN FRANCISCO, August 02, 2024--Tivic Health® Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the Virtual Annual General Meeting of Shareholders will be held on Friday, August 9, 2024 at 10:00 a.m., Pacific Time. The Company has adopted a virtual format for our Annual Meeting to provide a healthy, consistent, and convenient experience for all stockholders regardless of location.

Business Wire 5 months ago

TIVC
-4.68%
Tivic Health Expands Intellectual Property Portfolio

SAN FRANCISCO, July 23, 2024--Tivic Health® Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that it has received patent grants from the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO):

Business Wire 5 months ago

TIVC
-4.68%
Tivic Health: Christina Valauri Appointed to Board of Directors

SAN FRANCISCO, June 18, 2024--Tivic Health® Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to welcome Christina Valauri to its board of directors, effective July 1, 2024.

Business Wire 6 months ago

TIVC
-4.68%
Tivic Health Partners with the Feinstein Institutes to Advance its Patent-pending, Non-Invasive Cervical Vagus Nerve Stimulation; Begins Optimization of ncVNS for use in Clinical Indications

SAN FRANCISCO, May 22, 2024--Tivic Health® Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today it has initiated the second phase of its clinical work to advance its novel non-invasive cervical vagus nerve stimulation ("ncVNS"). The company has entered into a collaboration agreement with The Feinstein Institutes for Medical Research at Northwell Health to optimize its ncVNS device therapy for use in specific

Business Wire 7 months ago

TIVC
-4.68%
Tivic Reports First Quarter 2024 Financial Results and Subsequent Events

SAN FRANCISCO, May 15, 2024--Tivic Health® Systems, Inc. ("Tivic", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its first quarter 2024 financial results with discussion of subsequent events.

Business Wire 7 months ago

TIVC
-4.68%

Performance Overview

Return	TIVC	S&P 500
YTD	-13.46%	-1.08%
1-Year	-83.59%	+22.14%
3-Year	-99.91%	+25.41%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Tivic Health Systems, Inc. (TIVC)

CEO Letter to Shareholders Issued by Tivic Health

Tivic Health Systems Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$1.48 loss in 3Q 2023)

Tivic hits enrolment target for vagus nerve stimulation trial

Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update

Enrollment Complete in Tivic Health Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device

Tivic Health Validates European Patents in Great Britain, Germany, and France

Tivic Health Systems, Inc. to Report Third Quarter 2024 Financial Results on November 14

First Subject Enrolled in Tivic Health’s Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device

Tivic Health CEO Jennifer Ernst to Present at New York BioFuture 2024

Tivic Health Gets Institutional Review Board's Approval for ncVNS Optimization Study

Tivic Health Receives Approval from Institutional Review Board for ncVNS Optimization Study, Readies for Enrollment

Tivic Health Accelerates VNS Commercial Strategy Development

Tivic Health Appoints Lisa Wolf as Interim Chief Financial Officer

Tivic Reports Second Quarter 2024 Financial Results

Tivic Health to Report Q2 2024 Financial Results and Corporate Update on August 14th Via Conference Call and Webcast

Tivic Announces 2024 Annual Meeting of Stockholders

Tivic Health Expands Intellectual Property Portfolio

Tivic Health: Christina Valauri Appointed to Board of Directors

Tivic Health Partners with the Feinstein Institutes to Advance its Patent-pending, Non-Invasive Cervical Vagus Nerve Stimulation; Begins Optimization of ncVNS for use in Clinical Indications

Tivic Reports First Quarter 2024 Financial Results and Subsequent Events

Performance Overview